COVID-19 Update

We continue to monitor COVID-19 in our area. If there are changes in surgeries or other scheduled appointments, your provider will notify you. We continue to provide in-person care and telemedicine appointments.

Learn about our expanded patient care options and visitor guidelines.

General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts

Health

Active Surveillance for Kidney Cancer

This is the least invasive treatment option for kidney cancer. During active surveillance, the patient and urologist agree to observe the tumor by obtaining regular imaging. For some patients, no intervention is ever needed, while for others, a “trigger for intervention” is reached and therapy is initiated.

Patients with tumors less than 2 centimeters in size are ideal candidates for active surveillance due to the low likelihood that the tumor will spread during observation; however, patients with tumors up to 4 centimeters can be safely watched based on a number of factors:

  • Patients with poor kidney function. Since any intervention on the kidney can cause further deterioration of kidney function, these patients may be better off selecting active surveillance. In some patients, further decline in kidney function puts the patient at risk of needing dialysis. Dialysis, while lifesaving, may be associated with poor outcomes and a low quality of life. Ask your doctor about your creatinine level, which is an indicator of kidney function (normal is less than 1.5 mg/dl).
  • Patients with hereditary forms of kidney cancer. This includes patients with Von-Hippel-Lindau (VHL), Birt-Hogg-Dube (BHD) or other conditions in which patients are at risk of having multiple tumors on both sides. These tumors are typically placed on active surveillance until they reach 3 centimeters or larger.
  • Patients who have drug-eluting heart stents and need to be on a blood thinner. Kidney surgery/intervention can result in severe bleeding in these patients, and thus a period of active surveillance until they can come off the blood thinners may be helpful to avoid potentially serious complications.
  • Elderly patients who are medically fragile. Since the risk that the small kidney tumor spreads is low, in patients with a short life expectancy (less than 10 years) a discussion regarding active surveillance may be prudent. Many of these patients die with the kidney tumor rather than from the kidney tumor.
  • Patients who are experiencing or recovering from an active serious medical problem. A period of active surveillance until things stabilize should be entertained.
  • Patients who are extremely anxious about having surgery or do not wish to have treatment.

What are the so-called triggers for intervention?

The most common trigger for intervention is demonstrated tumor growth. As a tumor gets larger, the risk of having a cancer and a more aggressive cancer increases. The risk of spread for a tumor less than 2 centimeters is less than 1%. The risk is 1–2% for 3-centimeter tumors and 3–5% for 4-centimeter tumors. Change in the patient condition could also trigger intervention. For example, a patient who was having a heart attack when their 2.5-centimeter kidney tumor was discovered has now recovered one year later and is fit for surgery. This now triggers an intervention.

What does active surveillance entail?

Typically we advocate imaging every three to six months months for two years then every six to 12 months annually. The initial evaluation should include a complete staging evaluation (bloodwork, chest/abdomen/pelvis imaging) to exclude the possibility that the disease has already spread. We prefer CT or MRI for the initial evaluation and then alternate between CT, MRI, and ultrasound to minimize radiation to the patient and to comprehensively evaluate the tumor. The exact protocol is customized to the patient.

Can the tumor spread while on active surveillance?

The answer to this is unfortunately YES. However, for a well-selected patient the risk of this occurring on surveillance is very low (less than 2%). Each patient and tumor are unique, and this risk should be discussed with your urologist.

In patients who elect delayed intervention, are the results compromised?

A recent study* by Johns Hopkins urologists showed that a period of active surveillance did not alter results. In this study, patients delayed treatment of their small kidney mass by over one year. All were eventually treated with minimally invasive surgery successfully.

*(Gupta… Pierorazio, 2019.

Does Johns Hopkins have an active surveillance program for kidney tumors?

Yes. Pioneers in this area, Johns Hopkins urologists have a formal program for observation of kidney tumors in the appropriate patient. The program involves regular checkups and filling out questionnaires regarding quality of life, anxiety, and general well-being. This helps with decision-making throughout the surveillance process. In the event an intervention is eventually selected, the kidney cancer expert urologist can then help tailor the best therapy for the patient.

How do I enroll in active surveillance at Johns Hopkins?

After a detailed evaluation by one of our experts, the patient signs a consent form and is enrolled in our formal prospective registry for active surveillance. Please contact Phillip Pierorazio or Tina Wjalitz at 410-502-5984.

Request an Appointment

Find a Doctor
Find a Doctor